Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

This study has been completed.
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC Identifier:
First received: October 4, 2007
Last updated: July 16, 2015
Last verified: October 2007

Condition Intervention Phase
Pneumonia, Bacterial
Drug: daptomycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals LLC:

Study Start Date: July 2001
Study Completion Date: February 2002
Primary Completion Date: February 2002 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Provide signed and dated informed consent.
  2. Adults, 18 years of age or older of either gender and of any race weighing up to 150 kg. Female patients of childbearing potential MUST be nonpregnant (confirmed by negative serum pregnancy test), nonlactating, and must be willing to practice reliable birth control measures during and for at least 30 days after treatment with study drug(s).
  3. Have a new pulmonary infiltrate on chest radiograph.
  4. Exhibit at least two of the following clinical symptoms of pneumonia on history or physical:

    • Cough
    • Production of purulent sputum or change in character of sputum
    • Auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (dullness to percussion, bronchial breath sounds, or egophony)
    • Dyspnea or tachypnea
    • Documented fever, defined as body temperature >38.0 ºC (100.4 ºF) taken orally; >38.5 ºC (101.2 ºF) tympanically; or >39.0 ºC (102.2 ºF) rectally or hypothermia, defined as core body temperature of <35.0 ºC (95.0 ºF)
    • An elevated total peripheral white blood cell count (WBC >10,000/mm3); or >15% immature neutrophils (bands), regardless of total peripheral white count; or leukopenia with total WBC <4500/mm3.
    • Hypoxemia with a PO2 < 60 mmHg (on room air) or O2 saturation <90% on room air
  5. Pneumonia which requires hospitalization and intravenous therapy for at least 5 days.
  6. Willingness to participate in this study and to complete all follow-up assessments.

Exclusion Criteria:

  1. Patients with Grade V pneumonia (based on Fine Score; Attachment 8).
  2. Patients in respiratory failure or incipient respiratory failure if the patient is not a candidate for mechanical ventilation (for any reason).
  3. Any of the following pulmonary conditions that may preclude interpretation of study results:

    • Cystic fibrosis
    • Primary lung cancer or another malignancy metastatic to the lungs
    • Known bronchial obstruction or a history of post-obstructive pneumonia
    • Known or suspected active tuberculosis.
  4. Severe shock (systolic blood pressure <90 mm Hg for >30 minutes not corrected by fluid bolus).
  5. Clinical evidence of bacterial meningitis (based on lumbar puncture results).
  6. Severe renal impairment (calculated creatinine clearance <30 mL/min).
  7. Moribund clinical condition: high likelihood of death during the first 48 hours.
  8. If HIV positive, known CD4 counts <200/mm3 or evidence of Pneumocystis carinii pneumonia.
  9. Inability to tolerate ceftriaxone or history of allergy to beta-lactam antibiotics (history of rash alone will not exclude a patient).
  10. Any individual previously treated with a potentially effective anti-infective agent for > 24 hours (or one dosing day) within 72 hours of enrollment, or prior treatment with any investigational drug (including experimental biologic agents) in previous 30 days or prior therapy with daptomycin.
  11. Patients who must continue HMG-CoA reductase inhibitor therapy (e.g., simvastatin, lovastatin, etc.) during the study treatment period.
  12. Anticipation that a second non-protocol systemic antibiotic will be required.
  13. Induction chemotherapy within 2 weeks prior to enrollment (or exogenous therapies which are anticipated to result in PMN counts of <200 mm3 during Treatment Phase), or patients with severe neutropenia (<200 PMN cells/mm3).
  14. Patients considered unreliable to return for visits or to comply with study procedures.
  15. Progressive neoplastic disease (Note: patients with malignancies in remission are eligible).
  16. Women who are pregnant or nursing/lactating.
  17. Patients presenting with nosocomial pneumonia (i.e., <14 days after discharge from a skilled nursing facility or hospital with an initial hospitalization of >=3 days duration).
  18. Clinical suspicion of Legionella pneumonia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Cubist Pharmaceuticals LLC Identifier: NCT00540072     History of Changes
Other Study ID Numbers: DAP-CAP-00-08
Study First Received: October 4, 2007
Last Updated: July 16, 2015

Keywords provided by Cubist Pharmaceuticals LLC:
Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

Additional relevant MeSH terms:
Pneumonia, Bacterial
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents processed this record on April 21, 2017